Loading organizations...
§ Private Profile · Verona, Veneto, Italy
Biotech company developing diagnostic and therapeutic systems for autoimmune diseases, focused on immune self-tolerance using nanomaterials.
Diamante is a Verona, Italy-based biotechnology company that develops diagnostic and therapeutic systems for autoimmune diseases using nanomaterials and plant viruses. The organization focuses on restoring immune self-tolerance by displaying immunodominant peptides to produce high-value compounds for the healthcare sector. Its primary lead asset targets Rheumatoid Arthritis, with the company aiming to initiate phase 1 clinical trials by 2025. To support its ongoing research and a strong intellectual property strategy for global patent protection across markets including the United States, the enterprise has secured funding through European public grants and a syndicate of nine private investors. This financial backing includes capital from institutional firms like Arieli Capital and prominent lead investor Elena Paola Lanati, who recently joined the board of directors. Diamante was founded in 2016 by Valentina Garonzi, Linda Avesani, and Roberta Zampieri.
Diamante has raised $600K across 1 funding round.
Diamante has raised $600K in total across 1 funding round.
Diamante has raised $600K across 1 funding round. Most recently, it raised $600K Seed in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 17, 2023 | $600K Seed | Arieli Capital | Elena Paola Lanati, Angels4impact, Angels4Women | Announced |
Diamante has raised $600K in total across 1 funding round.
Diamante's investors include Arieli Capital, Elena Paola Lanati, Angels4Impact, Angels4Women.